| By PRNewswire |
| Tuesday, 26 August 2008 |
 |
Codexis, Inc., a leader in biocatalysis technology, and Arch Pharmalabs Limited, a
leading Indian active pharmaceutical ingredients (APIs) and intermediates
manufacturer, today announced a major new strategic collaboration, expanding
their three-year partnership in pharmaceuticals manufacturing. |
|
Codexis, based in
Redwood City, CA
, will offer multiple pharmaceutical
intermediates and active pharmaceutical ingredients (APIs) made with its
proprietary biocatalytic processes to both innovator and generic drug
manufacturers. Sales in
India
will be through its subsidiary, Codexis
Laboratories India Private Limited. Arch, which is based in
Mumbai, India
and
has ten facilities throughout the country, will be Codexis' exclusive
manufacturer for these products. The two companies will also co-market
products.
"Codexis and Arch will now offer a broad range of competitively-priced
drug ingredients to the global pharmaceutical industry. We believe this
collaboration offers a major opportunity for growth," said
Alan Shaw
, Ph.D.,
President and Chief Executive Officer of Codexis. "Market drivers for both
the innovator and generics sectors of the global pharmaceutical market are
converging, as both sectors accelerate their search for high quality manufacturing at the lowest possible cost. This new agreement is targeted at addressing this |
|
|
convergence, coupling proven biocatalysis technology with large-scale manufacturing capability. We are very pleased to be broadening our collaboration with Arch, which has become an important strategic part.
"Codexis and Arch have built a successful partnership over three years
based on anticipating customer needs and consistently meeting them in the
rapidly-growing global market for high quality, low-cost pharmaceutical
intermediates and APIs," said
Ajit Kamath
, Chairman and Managing Director,
Arch Pharmalabs Limited. "We are now well-positioned to build on this
success, serving the growing global demand for cost-effective, high-quality
pharmaceuticals."
Products to be sold under the new collaboration include the full range of
intermediates used to manufacture generic atorvastatin, as well as the API
itself. Atorvastatin is the active ingredient in Lipitor, the world's largest
selling drug used to lower cholesterol. Other planned future products include
generic intermediates and APIs for montelukast (asthma/allergy) and
esomeprazole (ulcers), as well as a key intermediate used in the manufacture
of the carbapenem class of antibiotics. Codexis and Arch began their
manufacturing collaboration in 2005.
Arch Pharmalabs Limited is a Mumbai, India -based company and leader in the manufacture of active pharmaceutical ingredients and |
|
leader in the
manufacture of active pharmaceutical ingredients and intermediates. Arch was
the recipient of the 2006 CNBC-ICICI Emerging India award in the
Pharmaceuticals & Chemicals category.
Codexis is a leading developer of proprietary biocatalysts that the
company believes have the potential to revolutionize chemistry-based
manufacturing processes across a variety of industries. The company has used
its technology platform to enable biocatalyst-based commercial-scale drug
manufacturing processes and delivered biocatalysts and drug products to some
of the world's leading pharmaceutical companies. Codexis has a funded
research collaboration in the biofuels market, and the company is pursuing
funded collaborations in several other bioindustrial markets, including carbon
management, water treatment and chemicals.
_____________________________
Want to read more?
_____________________________
Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
ScinoPharm Passes Japanese PMDA GMP Inspection
Rohm and Haas to Impose Indexed Raw Material Surcharge in Asia Pacific |
|
|
